vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $18.6M, roughly 1.6× ENANTA PHARMACEUTICALS INC). ENANTA PHARMACEUTICALS INC runs the higher net margin — -64.1% vs -438.1%, a 374.0% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 9.8%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 4.5%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
DOMH vs ENTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $18.6M |
| Net Profit | $-131.8M | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -60.5% |
| Net Margin | -438.1% | -64.1% |
| Revenue YoY | 220.4% | 9.8% |
| Net Profit YoY | -12426.2% | 46.4% |
| EPS (diluted) | $-6.94 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $18.6M | ||
| Q3 25 | $50.8M | $15.1M | ||
| Q2 25 | $34.1M | $18.3M | ||
| Q1 25 | $8.1M | $14.9M | ||
| Q4 24 | $9.4M | $17.0M | ||
| Q3 24 | $4.0M | $14.6M | ||
| Q2 24 | $6.2M | $18.0M | ||
| Q1 24 | $1.4M | $17.1M |
| Q4 25 | $-131.8M | $-11.9M | ||
| Q3 25 | $125.2M | $-18.7M | ||
| Q2 25 | $16.6M | $-18.3M | ||
| Q1 25 | $-32.5M | $-22.6M | ||
| Q4 24 | $1.1M | $-22.3M | ||
| Q3 24 | $-4.2M | $-28.8M | ||
| Q2 24 | $-6.1M | $-22.7M | ||
| Q1 24 | $-5.4M | $-31.2M |
| Q4 25 | -8.9% | -60.5% | ||
| Q3 25 | -3.1% | -121.6% | ||
| Q2 25 | -57.0% | -103.2% | ||
| Q1 25 | -394.6% | -164.3% | ||
| Q4 24 | 0.4% | -138.8% | ||
| Q3 24 | -79.1% | -204.4% | ||
| Q2 24 | -44.3% | -134.6% | ||
| Q1 24 | -205.2% | -192.1% |
| Q4 25 | -438.1% | -64.1% | ||
| Q3 25 | 246.4% | -123.6% | ||
| Q2 25 | 48.7% | -99.7% | ||
| Q1 25 | -400.5% | -151.7% | ||
| Q4 24 | 11.4% | -131.4% | ||
| Q3 24 | -104.2% | -197.3% | ||
| Q2 24 | -99.1% | -126.1% | ||
| Q1 24 | -398.0% | -182.7% |
| Q4 25 | $-6.94 | $-0.42 | ||
| Q3 25 | $7.27 | $-0.88 | ||
| Q2 25 | $1.12 | $-0.85 | ||
| Q1 25 | $-3.02 | $-1.06 | ||
| Q4 24 | $0.21 | $-1.05 | ||
| Q3 24 | $-0.67 | $-1.36 | ||
| Q2 24 | $-1.01 | $-1.07 | ||
| Q1 24 | $-0.91 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $126.6M |
| Total Assets | $112.9M | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $37.4M | ||
| Q3 25 | $176.2M | $32.3M | ||
| Q2 25 | $28.2M | $44.8M | ||
| Q1 25 | $18.9M | $60.2M | ||
| Q4 24 | $8.2M | $84.3M | ||
| Q3 24 | $7.2M | $37.2M | ||
| Q2 24 | $12.1M | $35.8M | ||
| Q1 24 | $7.1M | $63.5M |
| Q4 25 | $69.4M | $126.6M | ||
| Q3 25 | $210.2M | $64.7M | ||
| Q2 25 | $88.6M | $79.3M | ||
| Q1 25 | $42.4M | $93.5M | ||
| Q4 24 | $39.9M | $111.8M | ||
| Q3 24 | $38.3M | $128.8M | ||
| Q2 24 | $42.4M | $148.9M | ||
| Q1 24 | $47.7M | $166.1M |
| Q4 25 | $112.9M | $329.5M | ||
| Q3 25 | $223.4M | $280.7M | ||
| Q2 25 | $109.3M | $301.0M | ||
| Q1 25 | $52.3M | $323.0M | ||
| Q4 24 | $47.1M | $348.6M | ||
| Q3 24 | $43.4M | $376.7M | ||
| Q2 24 | $49.1M | $398.8M | ||
| Q1 24 | $52.2M | $413.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-11.7M |
| Free Cash FlowOCF − Capex | — | $-11.8M |
| FCF MarginFCF / Revenue | — | -63.6% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-11.7M | ||
| Q3 25 | $-4.9M | $-6.5M | ||
| Q2 25 | $-353.0K | $17.5M | ||
| Q1 25 | $1.2M | $-13.5M | ||
| Q4 24 | $-16.7M | $-16.8M | ||
| Q3 24 | $-4.7M | $-10.4M | ||
| Q2 24 | $1.4M | $-14.8M | ||
| Q1 24 | $-8.6M | $-28.6M |
| Q4 25 | — | $-11.8M | ||
| Q3 25 | — | $-7.9M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $-16.0M | ||
| Q4 24 | — | $-25.5M | ||
| Q3 24 | — | $-19.4M | ||
| Q2 24 | — | $-21.3M | ||
| Q1 24 | — | $-30.3M |
| Q4 25 | — | -63.6% | ||
| Q3 25 | — | -52.5% | ||
| Q2 25 | — | 94.7% | ||
| Q1 25 | — | -107.4% | ||
| Q4 24 | — | -150.6% | ||
| Q3 24 | — | -132.5% | ||
| Q2 24 | — | -118.6% | ||
| Q1 24 | — | -177.5% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | — | 51.6% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 36.4% | ||
| Q1 24 | — | 9.8% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
ENTA
Segment breakdown not available.
